Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AK111 injection in active ankylosing spondylitis (phase III)
CTR20233111Phase 3Completed
- Sponsor
- Akeso, Inc.
- Start
- Oct 2023
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 3 trial of gumokimab in ankylosing spondylitis (AS), sponsored by Akeso, Inc.. Started Oct 2023; status: completed.
02
Drugs
gumokimab
03
Conditions
ankylosing spondylitis (AS)
Beyond the preview
Go deeper on CTR20233111.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20233111.